Clinical Approach to Rash

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of rash

Rash is one of the most common presenting complaints in clinical practice, accounting for approximately 7% of all outpatient visits in the United States. Dermatological conditions represent the fourth most common reason for primary care consultations, with an estimated 85 million visits annually. The skin, as the body’s largest organ, serves as a window to both localized cutaneous disease and systemic illness. Approximately 15-20% of skin eruptions are manifestations of underlying systemic conditions, making accurate diagnosis crucial for patient management.

Definition

A rash (exanthem) is any change in the skin’s appearance, including alterations in color, texture, or elevation. It represents the cutaneous manifestation of various pathological processes including inflammation, infection, immune dysregulation, vascular abnormalities, or neoplastic proliferation. Rashes may be localized or generalized, symptomatic or asymptomatic, and may indicate primary skin disease or systemic illness.

Classification by Duration

Category	Duration	Common Causes	Clinical Significance
Acute	Less than 2 weeks	Viral exanthems, drug eruptions, acute urticaria, contact dermatitis, cellulitis	Often self-limiting; requires exclusion of serious causes such as drug hypersensitivity syndrome or sepsis
Subacute	2 to 6 weeks	Pityriasis rosea, secondary syphilis, persistent drug reactions, evolving autoimmune conditions	May represent resolving acute process or early chronic condition; warrants investigation if not improving
Chronic	Greater than 6 weeks	Psoriasis, eczema, chronic urticaria, lichen planus, cutaneous lupus, dermatomyositis	Often indicates underlying inflammatory, autoimmune, or neoplastic process; requires systematic evaluation

Classification by Primary Lesion Morphology

Key Concept: Accurate description of the primary lesion is the foundation of dermatological diagnosis. The morphology provides the most important clue to etiology.

Lesion Type	Definition	Clinical Examples
Macule	Flat, non-palpable lesion less than 1 cm; change in color only	Freckles, petechiae, vitiligo, measles early stage
Patch	Flat, non-palpable lesion greater than 1 cm	Vitiligo, café-au-lait spots, tinea versicolor
Papule	Elevated, palpable lesion less than 1 cm	Warts, molluscum contagiosum, lichen planus, insect bites
Plaque	Elevated, palpable lesion greater than 1 cm; often formed by coalescence of papules	Psoriasis, eczema, mycosis fungoides
Vesicle	Fluid-filled lesion less than 1 cm	Herpes simplex, varicella, dyshidrotic eczema
Bulla	Fluid-filled lesion greater than 1 cm	Bullous pemphigoid, pemphigus vulgaris, burns
Pustule	Pus-filled lesion of any size	Acne, folliculitis, pustular psoriasis
Wheal (Hive)	Transient, edematous, pink papule or plaque	Urticaria, angioedema
Nodule	Palpable, solid lesion greater than 1 cm extending into dermis or subcutis	Erythema nodosum, lipoma, cyst
Purpura	Non-blanching red-purple discoloration due to extravasated blood	Vasculitis, thrombocytopenia, senile purpura

Classification by Distribution Pattern

Localized Patterns

Dermatomal: Follows nerve distribution (herpes zoster)

Photo-distributed: Sun-exposed areas (drug photosensitivity, lupus)

Acral: Hands and feet (hand-foot-mouth disease, Rocky Mountain spotted fever)

Flexural: Body folds (atopic dermatitis, inverse psoriasis)

Extensor: Elbows and knees (psoriasis, dermatitis herpetiformis)

Generalized Patterns

Diffuse/Universal: Entire body surface (erythroderma, drug reactions)

Central: Trunk predominant (pityriasis rosea, viral exanthems)

Peripheral: Extremity predominant (erythema multiforme)

Symmetrical: Bilateral mirror distribution (systemic causes)

Asymmetrical: Unilateral or irregular (contact, infection)

Secondary Lesion Changes

Change	Description	Clinical Significance
Scale	Accumulation of stratum corneum	Suggests epidermal involvement (psoriasis, eczema, tinea)
Crust	Dried serum, blood, or pus on surface	Indicates prior vesicle, erosion, or infection (impetigo)
Erosion	Superficial loss of epidermis; heals without scarring	Secondary to vesicle rupture or superficial trauma
Ulcer	Loss of epidermis and dermis; heals with scarring	Vascular insufficiency, infection, malignancy, vasculitis
Lichenification	Thickening with accentuated skin markings	Chronic rubbing or scratching (chronic eczema)
Excoriation	Linear erosion from scratching	Indicates pruritus; look for primary lesions

The “Big Five” Approach: When evaluating any rash, systematically assess five key features:

Morphology: What is the primary lesion type?
Distribution: Where is it located and what pattern does it follow?
Arrangement: How are lesions grouped (clustered, linear, annular)?
Color: What color changes are present (erythema, hyperpigmentation, purpura)?
Associated symptoms: Is there pruritus, pain, or systemic symptoms?

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of cutaneous eruptions

Understanding the pathophysiology of rash requires knowledge of skin anatomy and the various mechanisms by which cutaneous inflammation and injury occur. The skin consists of three main layers: the epidermis (stratified squamous epithelium providing barrier function), the dermis (connective tissue containing blood vessels, nerves, and appendages), and the subcutis (adipose tissue). Rashes develop through disturbances in any of these layers via inflammatory, infectious, vascular, or neoplastic processes.

Relevant Skin Anatomy

Layer	Key Components	Role in Rash Formation
Epidermis	Keratinocytes, melanocytes, Langerhans cells, Merkel cells	Barrier disruption causes scaling and erosions; immune activation triggers inflammation; melanocyte dysfunction causes pigmentary changes
Dermoepidermal Junction	Basement membrane zone with hemidesmosomes and anchoring fibrils	Autoantibody targeting causes blistering diseases (bullous pemphigoid, epidermolysis bullosa acquisita)
Dermis	Collagen, elastin, blood vessels, lymphatics, mast cells, fibroblasts	Vascular dilation causes erythema; vessel damage causes purpura; edema causes wheals; inflammation causes papules and plaques
Subcutis	Adipose tissue, larger vessels, nerves	Panniculitis causes tender nodules (erythema nodosum); deep infections cause cellulitis

Immunological Mechanisms of Rash

Key Concept: Many rashes result from immune-mediated mechanisms. Understanding the Gell and Coombs classification of hypersensitivity reactions helps predict clinical features and guide management.

Type I: Immediate Hypersensitivity

Mechanism: IgE-mediated mast cell degranulation

Timing: Minutes to hours

Mediators: Histamine, leukotrienes, prostaglandins

Clinical examples: Urticaria, angioedema, anaphylaxis

Rash features: Wheals, erythema, pruritus; transient and migratory

Type II: Cytotoxic Hypersensitivity

Mechanism: IgG/IgM antibodies against cell surface antigens

Timing: Hours to days

Mediators: Complement activation, antibody-dependent cellular cytotoxicity

Clinical examples: Pemphigus vulgaris, bullous pemphigoid

Rash features: Blisters and erosions at sites of autoantibody binding

Type III: Immune Complex

Mechanism: Antigen-antibody complex deposition in vessel walls

Timing: Days to weeks

Mediators: Complement, neutrophil infiltration

Clinical examples: Leukocytoclastic vasculitis, serum sickness, lupus

Rash features: Palpable purpura, urticarial vasculitis, livedo

Type IV: Delayed Hypersensitivity

Mechanism: T-cell mediated inflammation

Timing: 24-72 hours to weeks

Mediators: Cytokines (interferon-gamma, tumor necrosis factor), cytotoxic T cells

Clinical examples: Contact dermatitis, drug eruptions, Stevens-Johnson syndrome

Rash features: Eczematous changes, morbilliform eruptions, bullae with necrosis in severe cases

How Common Conditions Cause Rash

Condition	Pathophysiological Mechanism	Clinical Correlation
Viral exanthem	Direct viral cytopathic effect on keratinocytes; immune complex deposition; T-cell response to viral antigens in skin	Morbilliform or maculopapular rash; often starts centrally and spreads peripherally; associated with prodromal symptoms
Drug eruption (morbilliform)	Type IVb hypersensitivity with CD4+ T-cell activation and cytokine release; typically 7-14 days after drug initiation	Symmetrical, erythematous macules and papules; may have mild pruritus; usually starts on trunk
Contact dermatitis	Type IVa hypersensitivity with Langerhans cell presentation of hapten to T cells; subsequent inflammatory cascade	Well-demarcated eczematous plaques conforming to area of contact; vesicles in acute phase; lichenification if chronic
Psoriasis	T-helper 17 cell-mediated inflammation with interleukin-17 and interleukin-23 axis activation; keratinocyte hyperproliferation (7-fold increase in turnover)	Well-demarcated erythematous plaques with silvery scale; Koebner phenomenon; nail changes; extensor distribution
Urticaria	Mast cell degranulation (IgE-mediated or direct); release of histamine causing vasodilation and increased vascular permeability	Transient wheals lasting less than 24 hours; intense pruritus; dermographism; individual lesion resolves completely
Cellulitis	Bacterial invasion (Streptococcus, Staphylococcus) of dermis and subcutis; inflammatory response with neutrophil infiltration; cytokine-mediated systemic response	Expanding area of erythema, warmth, tenderness; poorly defined borders; may have fever and leukocytosis
Vasculitis (small vessel)	Immune complex deposition or direct antibody attack on vessel walls; complement activation; neutrophilic infiltration with fibrinoid necrosis	Palpable purpura (non-blanching); lower extremity predominance; may have systemic involvement (kidneys, joints)
Stevens-Johnson syndrome/Toxic epidermal necrolysis	Type IVc hypersensitivity with CD8+ cytotoxic T cells and natural killer cells; massive keratinocyte apoptosis via Fas-Fas ligand and granulysin pathways	Mucosal erosions; targetoid lesions progressing to widespread epidermal detachment; positive Nikolsky sign; systemic toxicity

Non-Immunological Mechanisms

Vascular Mechanisms

Vasodilation: Erythema and blanching

Extravasation: Purpura and petechiae

Thrombosis: Livedo reticularis, necrosis

Clinical relevance: Distinguish blanching (vascular dilation) from non-blanching (hemorrhage) lesions with diascopy

Infectious Mechanisms

Direct invasion: Bacterial, fungal, viral cytopathic effects

Toxin-mediated: Staphylococcal scalded skin syndrome, scarlet fever

Embolic phenomena: Janeway lesions, Osler nodes

Clinical relevance: Pattern and morphology help identify organism and guide empiric therapy

Physical and Environmental

Mechanical: Friction, pressure (calluses, corns)

Thermal: Burns, frostbite

Radiation: Sunburn, radiation dermatitis

Clinical relevance: History of exposure is diagnostic; remove offending agent

Often Overlooked Mechanism: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

This severe drug reaction involves viral reactivation (particularly human herpesvirus 6) alongside drug hypersensitivity. The mechanism involves sequential drug-induced immunosuppression followed by viral reactivation, creating a “two-hit” model. This explains the characteristic delayed onset (2-8 weeks after drug exposure) and the prolonged, relapsing course even after drug discontinuation. Always check for hepatic, renal, and hematologic involvement in any patient with extensive drug eruption and eosinophilia.

Understanding Pruritus in Rash

Pruritus Pattern	Mechanism	Associated Conditions
Histamine-mediated	Mast cell degranulation activating H1 receptors on sensory nerves	Urticaria, insect bites; responds well to antihistamines
Non-histaminergic	Cytokines (interleukin-31), proteases, neuropeptides (substance P) activating C-fibers	Atopic dermatitis, psoriasis; poor antihistamine response
Neuropathic	Damage or dysfunction of peripheral or central sensory neurons	Postherpetic neuralgia, brachioradial pruritus, notalgia paresthetica
Psychogenic	Central nervous system processing abnormalities; often associated with anxiety or depression	Neurotic excoriations, delusions of parasitosis

Clinical Implication of Pathophysiology

Understanding the mechanism guides treatment selection. Histamine-driven urticaria responds to antihistamines, while interleukin-mediated inflammation in psoriasis requires immunomodulatory therapy. Type I reactions warrant epinephrine readiness, while type IV reactions benefit from corticosteroids. Identifying the mechanism early prevents ineffective therapy and guides appropriate intervention.

3. History Taking

A comprehensive approach to eliciting the rash history

Red Flags — Require Urgent Evaluation

Mucosal involvement — Stevens-Johnson syndrome, toxic epidermal necrolysis, pemphigus vulgaris
Skin pain out of proportion to appearance — Necrotizing fasciitis, early toxic epidermal necrolysis
Rapidly spreading erythema with systemic toxicity — Cellulitis, necrotizing soft tissue infection, sepsis
Petechiae or purpura with fever — Meningococcemia, Rocky Mountain spotted fever, disseminated intravascular coagulation

Blistering with positive Nikolsky sign — Toxic epidermal necrolysis, staphylococcal scalded skin syndrome, pemphigus
Facial swelling or tongue involvement — Angioedema, anaphylaxis (airway emergency)
Fever with diffuse erythema and hypotension — Toxic shock syndrome
New rash with eosinophilia and organ dysfunction — Drug reaction with eosinophilia and systemic symptoms (DRESS)

Systematic History: The “RASHES” Approach

Use the mnemonic “RASHES” to ensure comprehensive history taking:

R — Recent exposures and triggers: New medications (within 2-8 weeks), foods, contacts, travel, sick contacts, environmental exposures
A — Appearance and evolution: What did it look like initially? How has it changed? Spreading pattern? Color changes over time?
S — Symptoms associated: Pruritus, pain, burning? Fever, malaise, arthralgia, sore throat? Mucosal symptoms (mouth sores, eye irritation, genital lesions)?
H — History (personal and family): Previous similar episodes? Atopy (eczema, asthma, allergic rhinitis)? Autoimmune diseases? Family history of skin conditions?
E — Exact location and spread: Where did it start? Where has it spread? Distribution pattern? Symmetric or asymmetric?
S — Systemic review: Weight loss, night sweats, joint pain, photosensitivity, Raynaud phenomenon, dry eyes/mouth, dysphagia, muscle weakness?

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Drug eruption	Symmetric, starts on trunk, 7-14 days after new medication	“Have you started any new medications in the past 2 months, including over-the-counter drugs, supplements, or herbal remedies?”
Viral exanthem	Prodrome of fever, malaise; often in outbreak settings	“Did you have any flu-like symptoms, sore throat, or fever before the rash appeared? Has anyone around you been sick?”
Contact dermatitis	Well-demarcated, geometric shapes, exposed areas	“Have you been exposed to any new soaps, detergents, cosmetics, jewelry, plants, or occupational chemicals?”
Urticaria	Transient wheals, individual lesions last less than 24 hours	“Do individual spots come and go, or do they stay in the same place? How long does each spot last before fading?”
Psoriasis	Well-demarcated plaques with silvery scale, nail changes	“Have you noticed thick, scaly patches on your elbows, knees, or scalp? Any changes in your fingernails or toenails?”
Scabies	Intense nocturnal pruritus, burrows, household contacts	“Is the itching worse at night? Does anyone else in your household have similar symptoms?”
Herpes zoster	Dermatomal distribution, preceded by pain or tingling	“Did you have pain, tingling, or burning in that area before the rash appeared? Did you have chickenpox as a child?”
Cellulitis	Unilateral, warm, tender, expanding erythema	“Did you notice any cuts, insect bites, or skin breaks before the redness started? Is the area warm and tender?”
Vasculitis	Palpable purpura, lower extremity predominance	“Have you had any joint pain, abdominal pain, blood in your urine, or recent infections like a sore throat?”
Systemic lupus erythematosus	Malar rash, photosensitivity, multisystem involvement	“Does sun exposure make your rash worse or cause new lesions? Have you had joint pain, mouth sores, or unusual fatigue?”
Secondary syphilis	Non-pruritic, palm and sole involvement, generalized	“Have you had any painless sores on your genitals in the past few months? Does the rash involve your palms or soles?”

Medication and Social History

Medications Commonly Causing Rash

Antibiotics — Penicillins, sulfonamides, cephalosporins (morbilliform eruptions most common)
Anticonvulsants — Phenytoin, carbamazepine, lamotrigine (high risk for Stevens-Johnson syndrome and DRESS)
Allopurinol — High risk for severe cutaneous adverse reactions, especially in HLA-B*58:01 carriers
Nonsteroidal anti-inflammatory drugs — Fixed drug eruption, urticaria, photosensitivity
Angiotensin-converting enzyme inhibitors — Angioedema (can occur years after starting)
Chemotherapy agents — Hand-foot syndrome, radiation recall dermatitis
Checkpoint inhibitors — Immune-mediated dermatitis, vitiligo, bullous reactions
Targeted therapies — Epidermal growth factor receptor inhibitors cause acneiform eruptions

Social and Occupational History

Sexual history: Risk factors for syphilis, herpes simplex virus, human immunodeficiency virus (disseminated infections)
Travel history: Endemic mycoses, tropical infections, dengue, chikungunya
Occupation: Healthcare (scabies, latex allergy), construction (contact dermatitis), outdoor work (Lyme disease, photodermatoses)
Hobbies: Gardening (plant dermatitis), swimming (pool granuloma, hot tub folliculitis)
Pets and animals: Tinea, scabies variants, cat scratch disease
Living conditions: Crowding (scabies, bed bugs), homelessness (ectoparasites, infections)
Immunosuppression: Human immunodeficiency virus status, transplant, chemotherapy, biologics

Critical Timeline Questions

Time from Trigger to Rash	Likely Mechanism	Consider These Diagnoses
Minutes to hours	Type I hypersensitivity (IgE-mediated)	Urticaria, angioedema, anaphylaxis
24-72 hours	Type IV hypersensitivity (T-cell mediated)	Contact dermatitis, fixed drug eruption
7-14 days	Delayed T-cell sensitization	Morbilliform drug eruption, viral exanthem
2-8 weeks	Complex immune dysregulation with viral reactivation	DRESS syndrome, serum sickness-like reaction
Months to years after exposure	Chronic sensitization or autoimmunity	Chronic contact dermatitis, drug-induced lupus

History-Taking Pearl

Always ask about the first lesion. Where did it appear? What did it look like? The primary lesion and initial distribution often provide the most valuable diagnostic information. By the time patients present, secondary changes (excoriation, lichenification, impetiginization) may obscure the original morphology.

4. Physical Examination

A systematic head-to-toe approach for evaluating rash

Systematic Framework: Use the “Complete Skin Survey” approach. Examine the entire skin surface in good lighting, including often-missed areas: scalp, behind ears, axillae, umbilicus, interdigital spaces, nails, and mucous membranes. A focused examination limited to the chief complaint area frequently misses diagnostic clues.

General Inspection

Overall appearance: Well or ill-appearing? Signs of systemic toxicity (lethargy, altered mental status)?
Skin color: Pallor (anemia), jaundice (liver disease), generalized erythema (erythroderma, toxic shock syndrome)
Respiratory status: Signs of airway compromise (stridor, wheezing) in patients with angioedema or anaphylaxis
Hydration: Extensive skin loss leads to fluid and electrolyte derangements
Body habitus: Obesity predisposes to intertrigo; malnutrition causes specific dermatoses

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Temperature	Fever (greater than 38°C)	Suggests infection, drug hypersensitivity syndrome, vasculitis, or systemic inflammatory condition; high fever with rash requires urgent evaluation
Heart Rate	Tachycardia	May indicate sepsis, anaphylaxis, pain, or systemic inflammation; compensatory response in erythroderma with fluid shifts
Blood Pressure	Hypotension	Concerning for sepsis, anaphylaxis, or toxic shock syndrome; requires immediate intervention
Respiratory Rate	Tachypnea	May indicate systemic illness, anaphylaxis, or anxiety; assess for airway involvement in angioedema
Oxygen Saturation	Hypoxia	Anaphylaxis with bronchospasm, underlying pulmonary disease, severe systemic illness

Systematic Skin Examination

Step 1: Describe the Primary Lesion

Feature	What to Assess	Documentation Example
Morphology	Macule, papule, plaque, vesicle, bulla, pustule, nodule, wheal, purpura	“Erythematous papules coalescing into plaques”
Size	Measure in millimeters or centimeters	“3-5 mm papules” or “10 cm plaque”
Color	Erythematous, violaceous, hyperpigmented, hypopigmented, yellow, brown	“Salmon-pink plaques with silvery scale”
Surface	Smooth, scaly, crusted, verrucous, umbilicated	“Smooth-topped papules” or “thick adherent scale”
Border	Well-defined, ill-defined, raised, flat	“Sharply demarcated plaques” or “poorly defined erythema”

Step 2: Assess Distribution and Arrangement

Distribution Patterns

Generalized: Involves most of body surface (drug eruption, viral exanthem)

Localized: Confined to one region (contact dermatitis, herpes zoster)

Symmetric: Bilateral mirror image (systemic cause)

Photodistributed: Sun-exposed areas sparing shaded areas (lupus, drug photosensitivity)

Dermatomal: Follows nerve distribution (herpes zoster)

Acral: Hands and feet (secondary syphilis, hand-foot-mouth disease)

Arrangement Patterns

Grouped/Clustered: Herpes simplex, herpes zoster

Linear: Contact dermatitis (plant), Koebner phenomenon, dermatitis artefacta

Annular: Ring-shaped (tinea corporis, granuloma annulare, erythema migrans)

Reticular: Net-like (livedo reticularis)

Targetoid: Central dusky zone with surrounding rings (erythema multiforme)

Serpiginous: Snake-like, wavy (cutaneous larva migrans)

Step 3: Perform Key Maneuvers

Maneuver	Technique	Positive Finding Indicates
Diascopy	Press glass slide firmly against lesion and observe	Blanching = vascular dilation (erythema); Non-blanching = extravasated blood (purpura) or infiltration
Nikolsky sign	Apply lateral pressure to normal-appearing skin near lesion	Positive (skin shears off) = pemphigus vulgaris, toxic epidermal necrolysis, staphylococcal scalded skin syndrome
Asboe-Hansen sign	Apply pressure to intact blister	Blister extends laterally = intraepidermal blister (pemphigus)
Darier sign	Stroke a lesion firmly	Urtication (wheal and flare) = mastocytosis
Dermographism	Stroke normal skin with blunt object	Wheal formation along stroke line = urticaria, mastocytosis
Auspitz sign	Remove scale from plaque	Pinpoint bleeding = psoriasis
Wood lamp examination	Examine skin under ultraviolet A light in dark room	Coral-red = erythrasma; Blue-green = Pseudomonas; Bright white = vitiligo; Yellow-green = tinea capitis (some species)

Regional Examination: Don’t Miss These Areas

Head and Neck

Scalp: Psoriasis, seborrheic dermatitis, tinea capitis, folliculitis

Face: Malar rash (lupus), seborrheic dermatitis, rosacea, perioral dermatitis

Ears: Psoriasis (retroauricular), seborrheic dermatitis, contact dermatitis (jewelry)

Oral mucosa: Lichen planus, pemphigus, Stevens-Johnson syndrome, erythema multiforme

Trunk and Extremities

Axillae: Intertrigo, contact dermatitis, inverse psoriasis, acanthosis nigricans

Umbilicus: Psoriasis, contact dermatitis (nickel from belt buckles)

Extensor surfaces: Psoriasis, dermatitis herpetiformis

Flexural surfaces: Atopic dermatitis, inverse psoriasis

Hands, Feet, and Nails

Palms/Soles: Secondary syphilis, psoriasis, eczema, keratoderma, erythema multiforme

Web spaces: Scabies (pathognomonic), tinea pedis, candidiasis

Nails: Pitting (psoriasis), Beau lines, onycholysis, splinter hemorrhages

Periungual: Ragged cuticles (dermatomyositis), paronychia

Mucosal Examination

Always Examine Mucous Membranes

Mucosal involvement transforms many diagnoses from mild to severe. Stevens-Johnson syndrome requires mucosal involvement by definition. Always examine:

Oral cavity: Erosions, ulcers, white plaques, hemorrhagic crusting of lips
Conjunctivae: Injection, discharge, pseudomembrane formation (requires urgent ophthalmology consultation)
Nasal mucosa: Crusting, erosions
Genital mucosa: Erosions, ulcers (may require specific inquiry and examination)

Expected Findings by Etiology

Condition	Primary Lesion	Distribution	Key Examination Findings
Morbilliform drug eruption	Erythematous macules and papules	Trunk → extremities, symmetric	Spares palms/soles initially; no mucosal involvement; patient appears well
Urticaria	Wheals (edematous pink plaques)	Variable, migratory	Individual lesions last less than 24 hours; dermographism; no residual marking
Contact dermatitis	Vesicles on erythematous base → eczematous plaques	Geometric, corresponds to contactant	Sharp borders; spares areas without contact; linear streaks suggest plant exposure
Psoriasis	Well-demarcated erythematous plaques with silvery scale	Extensor surfaces, scalp, sacrum	Auspitz sign; nail pitting and onycholysis; Koebner phenomenon
Herpes zoster	Grouped vesicles on erythematous base	Dermatomal, unilateral	Does not cross midline; pain often precedes rash; Hutchinson sign (nose tip) indicates eye involvement
Cellulitis	Ill-defined erythematous patch/plaque	Unilateral, often lower extremity	Warmth, tenderness, expanding border; may have portal of entry; lymphangitic streaking
Erythema multiforme	Targetoid lesions with three zones	Acral predominance (palms, soles, dorsal hands)	True targets with dusky center, pale ring, erythematous halo; mucosal involvement variable
Stevens-Johnson syndrome	Atypical targets, macules, bullae	Trunk predominant initially	Mucosal erosions (at least 2 sites); positive Nikolsky sign; skin pain; less than 10% body surface area detachment
Leukocytoclastic vasculitis	Palpable purpura	Lower extremities, dependent areas	Non-blanching on diascopy; may have vesicles, ulcers, or necrosis; check for systemic involvement
Scabies	Papules, vesicles, burrows	Web spaces, wrists, axillae, periumbilical, genitalia	Burrows (pathognomonic); excoriations from scratching; spares head in adults

Important Teaching Point

Context determines significance. The physical examination findings must be interpreted in clinical context. A non-tender, well-appearing patient with scattered purpura likely has a benign cause (senile purpura, trauma), while purpura with fever and ill appearance suggests life-threatening infection or vasculitis. Similarly, a few vesicles on the lip are herpes labialis, but widespread vesicles with mucosal involvement and skin pain may be Stevens-Johnson syndrome. Always integrate examination findings with history and vital signs.

Examination Pearls

Photograph the rash: Rashes evolve; documentation aids diagnosis and follow-up
Palpate every rash: You cannot distinguish papules from macules, or detect purpura, without touch
Examine in good lighting: Subtle color changes and scale are missed in dim environments
Look for “unroofed” lesions: The edge of a ruptured blister or pustule reveals the depth of the lesion
Ask about timing of individual lesions: Wheals resolve in less than 24 hours; fixed lesions suggest different pathology

5. Differential Diagnosis

Systematic approach organized by probability, morphology, and clinical features

Acute Rash (Duration: Less than 2 weeks)

Probability	Condition	Key Features	Red Flags
COMMON (approximately 70%)	Viral exanthem	Morbilliform; prodrome of fever, malaise; often in outbreak setting	Petechiae, mucosal involvement, severe systemic symptoms
	Drug eruption (morbilliform)	Symmetric, trunk to extremities; 7-14 days after new medication	Facial edema, mucosal lesions, blistering, eosinophilia, organ dysfunction
	Urticaria (acute)	Migratory wheals; individual lesions last less than 24 hours; intense pruritus	Angioedema (lips, tongue, throat), respiratory symptoms, hypotension
	Contact dermatitis (acute)	Geometric distribution; vesicles on erythematous base; pruritic	Widespread involvement, systemic symptoms (suggests systemic contact)
	Cellulitis	Unilateral, expanding erythema; warmth, tenderness; portal of entry	Rapid progression, crepitus, pain out of proportion, bullae, necrosis
LESS COMMON (approximately 20%)	Herpes zoster	Dermatomal; grouped vesicles; preceded by pain	Dissemination, Hutchinson sign (eye involvement), immunocompromised host
	Erythema multiforme	Targetoid lesions; acral distribution; often post-herpes simplex virus	Mucosal involvement (may indicate Stevens-Johnson syndrome)
	Scabies	Burrows, web spaces; intense nocturnal pruritus; household contacts	Crusted (Norwegian) scabies in immunocompromised
	Insect bite reaction	Grouped papules; exposed areas; central punctum	Widespread urticaria, systemic symptoms (anaphylaxis)
UNCOMMON BUT SERIOUS (approximately 10%)	Stevens-Johnson syndrome / Toxic epidermal necrolysis	Atypical targets, bullae; mucosal erosions; skin pain; recent drug exposure	Greater than 10% body surface area (toxic epidermal necrolysis); high mortality
	Meningococcemia	Petechiae and purpura; fever; rapid progression; ill-appearing	All cases are emergent; purpura fulminans indicates disseminated intravascular coagulation
	Necrotizing fasciitis	Pain out of proportion; rapid spread; systemic toxicity; crepitus	Surgical emergency; mortality increases with delay
	Rocky Mountain spotted fever	Petechial rash starting on wrists/ankles → centripetal; fever, headache	Delay in treatment increases mortality; treat empirically if suspected
	Toxic shock syndrome	Diffuse erythroderma; fever; hypotension; multiorgan dysfunction	Emergent; requires intensive care unit admission

Chronic Rash (Duration: Greater than 6 weeks)

Step-by-Step Approach to Chronic Rash:

Step 1: Identify the primary lesion morphology — Is it papulosquamous, eczematous, vesiculobullous, or purpuric?
Step 2: Assess distribution — Does the pattern suggest a specific diagnosis (photodistributed, dermatomal, extensor)?
Step 3: Consider the “Big Four” causes of chronic rash — Eczema, psoriasis, fungal infection, and drug reaction
Step 4: Look for systemic clues — Joint pain, photosensitivity, oral ulcers, and other features suggesting connective tissue disease
Step 5: Consider biopsy if diagnosis remains unclear after clinical assessment

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Atopic dermatitis (eczema)	10-20% of population	Flexural distribution in adults; pruritus; personal or family history of atopy; lichenification
	Psoriasis	2-3% of population	Well-demarcated plaques with silvery scale; extensor surfaces; nail changes; Koebner phenomenon
	Seborrheic dermatitis	3-5% of population	Greasy yellow scale; nasolabial folds, eyebrows, scalp; may flare with stress
	Chronic urticaria	0.5-1% of population	Recurrent wheals for greater than 6 weeks; often idiopathic; individual lesions transient
LESS COMMON	Tinea corporis / Tinea cruris	Variable	Annular plaques with central clearing and active scaly border; potassium hydroxide positive
	Lichen planus	0.5-1% of population	Purple, polygonal, planar papules; Wickham striae; oral involvement common
	Pityriasis rosea	Variable (often subacute)	Herald patch followed by “Christmas tree” distribution; oval lesions along skin lines
	Nummular eczema	Variable	Coin-shaped eczematous plaques; often on extremities; very pruritic
UNCOMMON BUT IMPORTANT	Cutaneous lupus erythematosus	Rare	Photodistributed; malar rash sparing nasolabial folds; discoid lesions with scarring
	Dermatomyositis	Rare	Heliotrope rash (periorbital); Gottron papules (knuckles); proximal muscle weakness
	Cutaneous T-cell lymphoma (mycosis fungoides)	Rare	Patches and plaques in sun-protected areas (“bathing suit distribution”); may evolve over years
	Bullous pemphigoid	Rare (elderly)	Tense bullae on erythematous or normal skin; pruritus may precede blisters; elderly patients
	Pemphigus vulgaris	Rare	Flaccid bullae that rupture easily; oral erosions often first; positive Nikolsky sign

Morphology-Based Differential

Papulosquamous

Psoriasis

Lichen planus

Pityriasis rosea

Secondary syphilis

Tinea corporis

Seborrheic dermatitis

Eczematous

Atopic dermatitis

Contact dermatitis

Nummular eczema

Stasis dermatitis

Asteatotic eczema

Dyshidrotic eczema

Vesiculobullous

Herpes simplex / zoster

Bullous pemphigoid

Pemphigus vulgaris

Dermatitis herpetiformis

Stevens-Johnson syndrome

Contact dermatitis (acute)

Purpuric / Vascular

Leukocytoclastic vasculitis

Henoch-Schönlein purpura (IgA vasculitis)

Thrombocytopenia

Meningococcemia

Rocky Mountain spotted fever

Senile purpura

Drug-Induced Rash

Reaction Type	Common Culprits	Characteristics	Time to Resolution After Stopping
Morbilliform (exanthematous)	Penicillins, sulfonamides, cephalosporins, anticonvulsants, allopurinol	Symmetric macules and papules; starts on trunk; mild pruritus; spares face initially	1-2 weeks
Urticarial	Penicillins, nonsteroidal anti-inflammatory drugs, opioids, radiocontrast	Wheals, angioedema; may be IgE-mediated or direct mast cell activation	Hours to days
Fixed drug eruption	Trimethoprim-sulfamethoxazole, nonsteroidal anti-inflammatory drugs, tetracyclines, phenolphthalein	Round, dusky plaques; recur in same location with re-exposure; may blister	Days to weeks (hyperpigmentation may persist)
Photosensitivity	Tetracyclines (especially doxycycline), fluoroquinolones, thiazides, amiodarone	Exaggerated sunburn in sun-exposed areas; sharp cutoff at clothing lines	Days to weeks after stopping and sun avoidance
Stevens-Johnson syndrome / Toxic epidermal necrolysis	Sulfonamides, anticonvulsants (carbamazepine, phenytoin, lamotrigine), allopurinol, nonsteroidal anti-inflammatory drugs	Mucosal erosions; skin pain; atypical targets; epidermal detachment	Weeks to months; may have long-term sequelae
Drug reaction with eosinophilia and systemic symptoms (DRESS)	Anticonvulsants, allopurinol, sulfonamides, dapsone, minocycline	Facial edema; morbilliform rash; fever; lymphadenopathy; eosinophilia; hepatitis	Weeks to months; may relapse
Acute generalized exanthematous pustulosis	Antibiotics (especially beta-lactams), calcium channel blockers, hydroxychloroquine	Rapid onset of hundreds of sterile pustules on erythematous base; fever; neutrophilia	Less than 2 weeks (rapid resolution)
Drug-induced lupus	Hydralazine, procainamide, isoniazid, tumor necrosis factor inhibitors	Photosensitive rash; arthralgia; serositis; positive antihistone antibodies	Weeks to months after drug cessation
Lichenoid drug eruption	Thiazides, beta-blockers, antimalarials, gold, angiotensin-converting enzyme inhibitors	Resembles lichen planus; may have photodistribution; longer latency	Months (may persist long after stopping)

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Dermatomal vesicles	Herpes zoster	Start antiviral within 72 hours; assess for eye involvement
Targetoid lesions on palms	Erythema multiforme	Look for mucosal involvement; identify trigger (herpes simplex virus, drugs)
Silvery scale on elbows/knees	Psoriasis	Check nails, scalp, intergluteal cleft; screen for psoriatic arthritis
Burrows in web spaces	Scabies	Treat patient and all close contacts simultaneously; wash bedding
Annular plaque with central clearing	Tinea corporis (or granuloma annulare)	Potassium hydroxide preparation; if negative consider granuloma annulare
Malar rash sparing nasolabial folds	Systemic lupus erythematosus	Antinuclear antibody, complete blood count, urinalysis, comprehensive metabolic panel
Palpable purpura on lower extremities	Leukocytoclastic vasculitis	Urinalysis (glomerulonephritis); biopsy if diagnosis unclear
Rash on palms and soles (non-pruritic)	Secondary syphilis	Rapid plasma reagin or venereal disease research laboratory test; human immunodeficiency virus testing
Herald patch followed by “Christmas tree” pattern	Pityriasis rosea	Reassurance (self-limiting); consider rapid plasma reagin to exclude syphilis
Heliotrope rash with proximal weakness	Dermatomyositis	Creatine kinase, aldolase; electromyography; malignancy screening
Petechiae with fever and headache	Meningococcemia or Rocky Mountain spotted fever	Emergent blood cultures, lumbar puncture; empiric antibiotics immediately
Tense bullae in elderly patient	Bullous pemphigoid	Skin biopsy for histology and direct immunofluorescence

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical suspicion

Key Principle: Many rashes can be diagnosed clinically without laboratory testing. Investigations should be targeted based on the differential diagnosis, not ordered as a “rash panel.” The clinical examination remains the most important diagnostic tool in dermatology.

Baseline Investigations for Selected Patients

Not all patients with rash require laboratory testing. Consider baseline investigations when:

Systemic symptoms are present (fever, malaise, weight loss)
Rash is widespread or severe
Drug hypersensitivity syndrome is suspected
Autoimmune or inflammatory condition is considered
Diagnosis is uncertain after clinical assessment

Investigation	Purpose	What to Look For	Practical Points
Complete blood count with differential	Screen for infection, eosinophilia, cytopenias	Eosinophilia (drug reaction, parasites); atypical lymphocytes (viral); leukocytosis (infection); thrombocytopenia (vasculitis, disseminated intravascular coagulation)	Eosinophilia greater than 1.5 × 10⁹/L with rash suggests drug reaction; peripheral smear if atypical cells
Comprehensive metabolic panel	Assess organ function, especially liver and kidney	Elevated transaminases (DRESS, hepatitis); renal dysfunction (vasculitis, drug toxicity)	Essential in suspected drug hypersensitivity; transaminases greater than 3 times upper limit of normal is significant
Urinalysis	Screen for renal involvement	Hematuria, proteinuria (vasculitis, lupus nephritis, IgA vasculitis)	Critical in vasculitis workup; repeat if initially normal but clinical suspicion high
Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein)	Assess degree of systemic inflammation	Elevation suggests infection, vasculitis, autoimmune disease	Non-specific; useful for monitoring but rarely diagnostic alone
Blood cultures	Identify bacteremia in suspected infectious etiology	Positive cultures guide antibiotic therapy	Obtain before antibiotics if sepsis, endocarditis, or meningococcemia suspected

Targeted Investigations by Suspected Etiology

If Suspecting Drug Hypersensitivity Syndrome (DRESS)

First-Line Tests

Complete blood count with differential: Eosinophilia (greater than 0.7 × 10⁹/L) or atypical lymphocytes
Liver function tests: Alanine aminotransferase greater than 2 times upper limit of normal
Renal function: Creatinine elevation indicates renal involvement

Second-Line Tests

Human herpesvirus 6 polymerase chain reaction: Reactivation supports DRESS diagnosis
Echocardiogram: If myocarditis suspected (chest pain, troponin elevation)
Thyroid function: Check at presentation and 2-3 months later (autoimmune thyroiditis can develop)

If Suspecting Autoimmune or Connective Tissue Disease

First-Line Tests

Antinuclear antibody: Screening test; positive in lupus, dermatomyositis, scleroderma
Complete blood count: Cytopenias (autoimmune)
Urinalysis: Renal involvement in lupus
Complement levels (C3, C4): Low in active lupus

Second-Line Tests (if antinuclear antibody positive)

Anti-double-stranded DNA: Specific for systemic lupus erythematosus
Anti-Smith, anti-ribonucleoprotein: Lupus and mixed connective tissue disease
Anti-Ro (SSA), anti-La (SSB): Subacute cutaneous lupus, Sjögren syndrome
Creatine kinase, aldolase: If dermatomyositis suspected
Myositis-specific antibodies: Anti-Jo-1, anti-Mi-2 for dermatomyositis

If Suspecting Vasculitis

First-Line Tests

Urinalysis: Hematuria, red blood cell casts (glomerulonephritis)
Renal function: Creatinine elevation
Inflammatory markers: Erythrocyte sedimentation rate, C-reactive protein elevated
Skin biopsy: Leukocytoclastic vasculitis; direct immunofluorescence for IgA (IgA vasculitis)

Second-Line Tests

Antineutrophil cytoplasmic antibody: If systemic vasculitis suspected (granulomatosis with polyangiitis, microscopic polyangiitis)
Cryoglobulins: If cryoglobulinemic vasculitis suspected (hepatitis C associated)
Hepatitis B and C serology: Associated with vasculitis
Complement levels: Low in hypocomplementemic urticarial vasculitis

If Suspecting Infection

Bacterial Infections

Blood cultures: Before antibiotics in sepsis, endocarditis
Wound culture: If purulent drainage or abscess present
Antistreptolysin O titer: Post-streptococcal vasculitis, guttate psoriasis trigger
Rapid plasma reagin or venereal disease research laboratory: Syphilis screening

Viral and Other Infections

Human immunodeficiency virus antibody/antigen: New diagnosis may present with rash; affects differential
Hepatitis panel: Hepatitis B and C associated with vasculitis, urticaria
Herpes simplex virus polymerase chain reaction or direct fluorescent antibody: Vesicular lesions
Varicella-zoster virus polymerase chain reaction: Atypical presentations or immunocompromised

Skin Biopsy: When and How

Indications for Skin Biopsy

Diagnosis uncertain after clinical assessment
Suspected malignancy (cutaneous T-cell lymphoma, melanoma)
Suspected autoimmune blistering disease (requires direct immunofluorescence)
Vasculitis confirmation
Chronic rash unresponsive to empiric treatment
Atypical presentation requiring histological characterization

Biopsy Type	Technique	Best For	Special Considerations
Punch biopsy (4 mm)	Circular blade removes full-thickness specimen	Most inflammatory conditions; vasculitis; panniculitis	Standard technique; include dermis and subcutis for panniculitis
Shave biopsy	Superficial horizontal excision	Epidermal lesions; suspected basal cell or squamous cell carcinoma	Inadequate for melanoma; does not assess depth
Incisional biopsy	Elliptical excision of portion of lesion	Large lesions; panniculitis; deep processes	Include subcutaneous fat for panniculitis
Direct immunofluorescence	Separate specimen in Michel medium (not formalin)	Autoimmune blistering diseases; lupus; vasculitis	Biopsy perilesional skin for bullous diseases; lesional skin for lupus

Bedside Diagnostic Tests

Test	Technique	Interpretation	Conditions Diagnosed
Potassium hydroxide (KOH) preparation	Scrape scale onto slide; add 10-20% KOH; heat gently; examine under microscope	Hyphae and/or spores visible	Dermatophyte infections (tinea), candidiasis
Tzanck smear	Scrape base of vesicle; stain with Giemsa or Wright stain	Multinucleated giant cells	Herpes simplex virus, varicella-zoster virus (does not distinguish between them)
Scabies preparation	Apply mineral oil; scrape burrow; examine under microscope	Mites, eggs, or fecal pellets (scybala)	Scabies
Wood lamp examination	Examine skin under ultraviolet A (365 nm) in dark room	Coral-red (erythrasma), blue-green (Pseudomonas), bright white (vitiligo)	Erythrasma, tinea capitis (some species), vitiligo, Pseudomonas infection
Dermoscopy	Examine lesion with polarized or non-polarized dermatoscope	Pattern recognition for pigmented and non-pigmented lesions	Melanoma, basal cell carcinoma, scabies (burrows), psoriasis (red dots)

Empiric Treatment Trials as Diagnostic Tools

Sequential Empiric Therapy Approach

When diagnosis is uncertain but clinical suspicion is high, empiric treatment trials can serve as diagnostic tools. Response to therapy supports the diagnosis. This approach is particularly useful for conditions where definitive testing is invasive, unavailable, or has limited sensitivity.

Suspected contact dermatitis: Remove suspected contactant and apply topical corticosteroid for 2 weeks — clearance supports diagnosis
Suspected tinea: Topical antifungal for 2-4 weeks — response suggests fungal etiology (if KOH negative or unavailable)
Suspected scabies: Permethrin treatment for patient and contacts — resolution of pruritus in 2-4 weeks supports diagnosis
Suspected drug eruption: Discontinue suspected medication — improvement within 1-2 weeks supports drug etiology

When to Refer to Dermatology

Situation	Urgency	Reason
Stevens-Johnson syndrome / Toxic epidermal necrolysis	EMERGENT	Requires specialized care; potential burn unit transfer; high mortality
Suspected pemphigus or pemphigoid with active blistering	URGENT	Biopsy with direct immunofluorescence required; needs systemic immunosuppression
Suspected cutaneous malignancy	URGENT	Biopsy and staging required; delays worsen outcomes
Chronic rash unresponsive to treatment	ROUTINE	May benefit from biopsy, patch testing, or specialized therapy
Diagnostic uncertainty	ROUTINE	Dermatology expertise in pattern recognition and biopsy interpretation

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Petechiae/purpura with fever, hypotension, or altered mental status	EMERGENT	Obtain blood cultures; start broad-spectrum antibiotics immediately; do not wait for results; consider meningococcemia, Rocky Mountain spotted fever
Widespread blistering with mucosal involvement and skin pain	EMERGENT	Stop all non-essential medications; calculate body surface area involvement; consult dermatology and burn unit; supportive care; consider Stevens-Johnson syndrome/toxic epidermal necrolysis
Rapidly spreading erythema with pain out of proportion, crepitus, or necrosis	EMERGENT	Surgical consultation immediately; broad-spectrum antibiotics; imaging if diagnosis uncertain; do not delay for imaging if clinical suspicion high; consider necrotizing fasciitis
Urticaria with angioedema, stridor, or hypotension	EMERGENT	Intramuscular epinephrine; secure airway; intravenous fluids; antihistamines and corticosteroids; observe for biphasic reaction
Diffuse erythroderma with fever and hypotension	EMERGENT	Fluid resuscitation; assess for toxic shock syndrome; blood cultures; remove tampons or wound packing; broad-spectrum antibiotics
Drug rash with fever, facial edema, lymphadenopathy, or eosinophilia	URGENT	Stop culprit drug immediately; check complete blood count, liver function tests, renal function; consider drug reaction with eosinophilia and systemic symptoms (DRESS); may need admission
Dermatomal vesicles involving the face (V1 distribution)	URGENT	Start antiviral within 72 hours; urgent ophthalmology referral (Hutchinson sign or any eye symptoms); assess for herpes zoster ophthalmicus
Expanding cellulitis not responding to oral antibiotics	URGENT	Admit for intravenous antibiotics; mark borders; consider resistant organisms, abscess, or alternative diagnosis
Chronic rash without red flags	ROUTINE	Outpatient evaluation; systematic workup; dermatology referral if diagnosis uncertain or treatment refractory
Localized, non-progressive rash in well-appearing patient	ROUTINE	Clinical diagnosis; empiric treatment if appropriate; follow-up to assess response

Step 2: Classify by Acuity and Morphology

Acute Rash (less than 2 weeks)

Proceed to Algorithm A

Focus on: infections, drug reactions, urticaria, contact dermatitis

Subacute Rash (2-6 weeks)

Proceed to Algorithm B

Focus on: pityriasis rosea, secondary syphilis, resolving acute process, early chronic condition

Chronic Rash (greater than 6 weeks)

Proceed to Algorithm C

Focus on: eczema, psoriasis, autoimmune conditions, cutaneous malignancy

Step 3: Follow the Appropriate Algorithm

Algorithm A: Acute Rash

Clinical Scenario	Most Likely Diagnosis	Action
Symmetric morbilliform rash + new medication in past 2 weeks + no mucosal involvement	Morbilliform drug eruption	Stop suspected drug; supportive care with antihistamines and topical corticosteroids; monitor for progression
Migratory wheals + individual lesions resolve in less than 24 hours + no residual marks	Acute urticaria	Identify and avoid trigger; second-generation antihistamine; short course of corticosteroids if severe
Geometric/linear vesicles on erythematous base + exposed area + history of exposure	Allergic contact dermatitis	Remove contactant; topical corticosteroid (high potency); oral corticosteroids if widespread
Grouped vesicles + dermatomal distribution + preceded by pain	Herpes zoster	Antiviral within 72 hours; pain management; ophthalmology if facial involvement
Unilateral warm, tender, expanding erythema + portal of entry	Cellulitis	Antibiotics covering Streptococcus and Staphylococcus; mark borders; elevate affected limb
Morbilliform rash + prodrome of fever/malaise + sick contacts or outbreak	Viral exanthem	Supportive care; isolate if measles suspected; consider testing if epidemiologically relevant
Targetoid lesions on palms/soles + recent herpes simplex virus infection	Erythema multiforme	Examine mucous membranes; supportive care; treat herpes simplex virus if active; prophylaxis if recurrent

Algorithm B: Subacute Rash (2-6 weeks)

Clinical Scenario	Most Likely Diagnosis	Action
Herald patch followed by oval papulosquamous lesions along skin lines (“Christmas tree” pattern)	Pityriasis rosea	Reassurance (self-limiting in 6-8 weeks); symptomatic treatment for pruritus; consider rapid plasma reagin to exclude syphilis
Non-pruritic papulosquamous rash + palm/sole involvement + lymphadenopathy	Secondary syphilis	Rapid plasma reagin and confirmatory testing; treat with penicillin; human immunodeficiency virus testing; contact tracing
Acute rash persisting beyond expected course + still improving	Resolving acute process	Continue current management; monitor for complete resolution; investigate further if not improving
New rash with systemic symptoms + drug started 2-8 weeks ago	Drug reaction with eosinophilia and systemic symptoms (DRESS)	Stop drug immediately; check complete blood count with differential, liver function tests, renal function; admit if organ involvement

Algorithm C: Chronic Rash (greater than 6 weeks)

Clinical Scenario	Most Likely Diagnosis	Action
Pruritic eczematous patches in flexural areas + personal/family history of atopy	Atopic dermatitis	Emollients; topical corticosteroids; trigger avoidance; consider calcineurin inhibitors for face/folds
Well-demarcated erythematous plaques with silvery scale + extensor surfaces + nail changes	Psoriasis	Topical therapy (corticosteroids, vitamin D analogues); phototherapy or systemic therapy if extensive; screen for psoriatic arthritis
Annular scaly plaques with central clearing + positive potassium hydroxide preparation	Tinea corporis	Topical antifungal for limited disease; oral antifungal if extensive, follicular involvement, or treatment failure
Recurrent wheals for greater than 6 weeks + individual lesions transient + no identifiable trigger	Chronic spontaneous urticaria	Second-generation antihistamine (up to 4 times standard dose); omalizumab if refractory; limited workup unless atypical features
Photodistributed rash + malar erythema sparing nasolabial folds + systemic symptoms	Cutaneous lupus erythematosus	Antinuclear antibody and serologic workup; sun protection; topical corticosteroids; hydroxychloroquine; rheumatology referral
Persistent patches/plaques in sun-protected areas + older patient + no response to topical treatment	Cutaneous T-cell lymphoma (mycosis fungoides)	Skin biopsy (may need multiple); dermatology and oncology referral; staging workup

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient develops rash while hospitalized on multiple new medications	Review medication timeline; stop most likely culprit (usually most recently started); examine for mucosal involvement and systemic signs	Monitor closely; if DRESS suspected, check complete blood count, liver function tests, renal function daily; dermatology consultation
Rash with unclear morphology due to excoriations	Look for primary lesions at periphery of affected area; ask patient to describe initial appearance; examine areas patient cannot scratch	If unable to identify primary lesion, treat symptomatically and reassess when excoriations heal; consider biopsy of intact lesion
Widespread rash in immunocompromised patient	Broaden differential to include opportunistic infections (disseminated herpes, fungal); lower threshold for biopsy and cultures	Consider varicella-zoster virus and herpes simplex virus polymerase chain reaction; fungal cultures; tissue biopsy; infectious disease consultation
Elderly patient with new tense bullae	Consider bullous pemphigoid; examine oral mucosa; assess Nikolsky sign	Skin biopsy for histology and direct immunofluorescence (perilesional skin); start moderate-potency topical corticosteroid while awaiting results
Rash that looks like psoriasis but patient has human immunodeficiency virus	Consider seborrheic dermatitis, psoriasis (may be more severe in human immunodeficiency virus), or secondary syphilis	Rapid plasma reagin test; standard psoriasis treatment (but avoid systemic immunosuppression if CD4 low); optimize human immunodeficiency virus treatment
Contact dermatitis but cannot identify contactant	Detailed history of all products used on skin, occupation, hobbies; consider airborne or systemic contact	Referral for patch testing; systematic elimination of suspected products
Chronic rash unresponsive to empiric treatment	Reassess diagnosis; consider biopsy if not already performed; evaluate for treatment adherence	Dermatology referral; consider alternative diagnoses (cutaneous T-cell lymphoma, drug eruption from chronic medication)

Troubleshooting Refractory Rash

Ask These Questions When Rash Does Not Respond

Is the diagnosis correct? — Consider biopsy if not already done; reassess morphology and distribution
Is there ongoing exposure? — Contact allergen still present; medication not discontinued; infection source not eliminated
Is treatment adequate? — Corticosteroid potency appropriate; duration sufficient; coverage for actual organism
Is the patient adherent? — Applying enough medication; completing full course; using as directed
Are there multiple overlapping conditions? — Contact dermatitis superimposed on atopic dermatitis; secondary infection complicating primary rash
Is there secondary infection? — Impetiginization of eczema; bacterial superinfection requiring antibiotics
Are there underlying factors? — Undiagnosed human immunodeficiency virus; diabetes; malignancy; medication causing or exacerbating rash

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

The primary lesion is paramount: Identifying the primary lesion morphology (macule, papule, vesicle, pustule, wheal) is the single most important step in dermatological diagnosis. Secondary changes from scratching or treatment obscure the diagnosis.

Distribution tells the story: Symmetric distribution suggests systemic cause (drug, viral, autoimmune). Asymmetric or localized distribution suggests external cause (contact, infection). Dermatomal distribution is virtually pathognomonic for herpes zoster.

Diascopy distinguishes erythema from purpura: Press a glass slide against the lesion. Blanching indicates vasodilation (erythema). Non-blanching indicates extravasated blood (purpura) and demands a different differential including vasculitis, coagulopathy, and sepsis.

Mucosal involvement changes everything: A morbilliform drug rash is usually benign, but mucosal erosions transform it into potential Stevens-Johnson syndrome. Always examine the oral cavity, conjunctivae, and ask about genital symptoms.

Drug timing guides suspicion: Type I reactions occur within minutes to hours. Morbilliform eruptions occur 7-14 days after starting a new drug. Drug reaction with eosinophilia and systemic symptoms (DRESS) occurs 2-8 weeks after initiation. Fixed drug eruption recurs within hours of re-exposure.

Wheals that persist beyond 24 hours are not simple urticaria: True urticarial lesions resolve completely within 24 hours and leave no mark. If individual lesions persist longer or leave bruising, consider urticarial vasculitis and perform biopsy.

Always consider syphilis: Secondary syphilis is “the great imitator” and can present with almost any morphology. A non-pruritic rash involving the palms and soles should prompt serologic testing, especially in sexually active patients.

Photograph every rash: Rashes evolve rapidly. A photograph at presentation provides invaluable documentation for comparison, consultation, and follow-up assessment.

Critical Pitfalls to Avoid

Dismissing skin pain: Pain out of proportion to visible findings is a red flag for necrotizing fasciitis and early toxic epidermal necrolysis. A patient who says their skin “hurts” rather than “itches” requires careful evaluation.

Attributing all rashes to allergy: Not every rash is allergic. Viral exanthems, autoimmune conditions, infections, and malignancies can all present with rash. A thorough differential prevents delayed diagnosis of serious conditions.

Missing drug reaction with eosinophilia and systemic symptoms (DRESS): This severe reaction presents 2-8 weeks after drug initiation with facial edema, rash, fever, and eosinophilia. The delayed onset often leads to missed diagnosis. Always check liver function tests, renal function, and complete blood count in any patient with extensive drug eruption.

Treating cellulitis without considering mimics: Stasis dermatitis, deep vein thrombosis, contact dermatitis, and gout can all mimic cellulitis. Bilateral “cellulitis” is almost never bilateral infection—consider stasis dermatitis. Failure to respond to antibiotics should prompt reconsideration of the diagnosis.

Ignoring the immunocompromised host: In immunocompromised patients, common conditions present atypically, and unusual infections must be considered. Disseminated herpes, invasive fungal infections, and drug reactions may all look different. Have a lower threshold for biopsy and cultures.

Applying topical steroids to undiagnosed facial rash: High-potency topical corticosteroids on the face can cause steroid rosacea, atrophy, and telangiectasia. Never prescribe potent topical steroids for facial rash without a clear diagnosis and plan for limited duration.

Forgetting to examine the whole skin: A focused examination of only the chief complaint area misses important diagnostic clues. Nail changes, scalp involvement, oral lesions, and genital findings often clinch the diagnosis.

Delaying treatment for Rocky Mountain spotted fever: This infection has significant mortality if treatment is delayed. Empiric doxycycline should be started immediately based on clinical suspicion (fever, headache, rash, tick exposure) without waiting for serologic confirmation.

Key Takeaways

Accurate description of the primary lesion morphology is the foundation of dermatological diagnosis—learn the vocabulary and use it precisely.
Red flags requiring urgent evaluation include mucosal involvement, skin pain, petechiae or purpura with fever, widespread blistering, and rapidly spreading erythema with systemic toxicity.
Use the “RASHES” mnemonic for systematic history: Recent exposures, Appearance and evolution, Symptoms associated, History personal and family, Exact location and spread, Systemic review.
Distribution pattern provides critical diagnostic clues: symmetric suggests systemic, dermatomal suggests zoster, photodistributed suggests lupus or drug photosensitivity, acral suggests erythema multiforme or secondary syphilis.
Drug eruptions have predictable timing: minutes to hours for urticaria/anaphylaxis, 7-14 days for morbilliform eruption, 2-8 weeks for drug reaction with eosinophilia and systemic symptoms (DRESS).
Always perform diascopy on any red or purple lesion to distinguish blanching erythema from non-blanching purpura—this fundamentally changes the differential diagnosis.
Many rashes are diagnosed clinically without laboratory testing. Target investigations based on clinical suspicion rather than ordering a “rash panel.”
When diagnosis is uncertain, skin biopsy is valuable—but the site and technique matter. Biopsy an established lesion, include adequate depth, and send for direct immunofluorescence if autoimmune blistering disease is suspected.
Consider secondary syphilis in any patient with a non-pruritic rash involving the palms and soles—serologic testing is simple and the diagnosis is easily missed.
If a rash is not responding to treatment, reassess the diagnosis. Consider biopsy, alternative diagnoses, ongoing exposure, inadequate treatment, non-adherence, or secondary infection.

Quick Reference Algorithm

Systematic Approach to Rash:

Assess urgency: Check for red flags (mucosal involvement, skin pain, petechiae with fever, widespread blistering, systemic toxicity). If present, initiate urgent workup and treatment.
Identify the primary lesion: Is it a macule, papule, plaque, vesicle, bulla, pustule, wheal, nodule, or purpura? This narrows the differential immediately.
Characterize the distribution: Localized versus generalized? Symmetric versus asymmetric? Photodistributed, dermatomal, flexural, extensor, or acral?
Take a focused history: Use “RASHES” mnemonic. Pay special attention to recent medications (past 8 weeks), timeline of evolution, associated symptoms, and exposures.
Perform key examination maneuvers: Diascopy for any red or purple lesion. Nikolsky sign if blistering. Dermoscopy if available. Examine nails, scalp, and mucous membranes.
Generate a probability-based differential: Start with common causes, but always consider serious diagnoses that require urgent treatment.
Target investigations: Order tests based on clinical suspicion, not as a routine panel. Consider biopsy if diagnosis remains unclear.
Initiate treatment and arrange follow-up: Treat empirically if diagnosis is confident. Reassess if no improvement. Refer to dermatology for refractory or diagnostically challenging cases.